Emergent Biosolutions Inc [NYSE: EBS] jumped around 0.79 points on Wednesday, while shares priced at $7.57 at the close of the session, up 11.65%.
Compared to the average trading volume of 2.67M shares, EBS reached a trading volume of 3423068 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
What do top market gurus say about Emergent Biosolutions Inc [EBS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EBS shares is $8.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EBS stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Benchmark Company have made an estimate for Emergent Biosolutions Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 07, 2024. While these analysts kept the previous recommendation, JP Morgan raised their target price to Underweight. The new note on the price target was released on November 20, 2023, representing the official price target for Emergent Biosolutions Inc stock.
The Average True Range (ATR) for Emergent Biosolutions Inc is set at 1.50, with the Price to Sales ratio for EBS stock in the period of the last 12 months amounting to 0.36. The Price to Book ratio for the last quarter was 1.04, with the Price to Cash per share for the same quarter was set at 1.34. Price to Free Cash Flow for EBS in the course of the last twelve months was 10.65 with Quick ratio for the last quarter at 0.54.
How has EBS stock performed recently?
Emergent Biosolutions Inc [EBS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.34. With this latest performance, EBS shares dropped by -37.49% in over the last four-week period, additionally plugging by 376.10% over the last 6 months – not to mention a rise of 37.89% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EBS stock in for the last two-week period is set at 43.07, with the RSI for the last a single of trading hit 41.08, and the three-weeks RSI is set at 45.49 for Emergent Biosolutions Inc [EBS]. The present Moving Average for the last 50 days of trading for this stock 8.75, while it was recorded at 7.30 for the last single week of trading, and 4.15 for the last 200 days.
Emergent Biosolutions Inc [EBS]: Deeper insight into the fundamentals
Emergent Biosolutions Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.54 and a Current Ratio set at 1.06.
Insider trade positions for Emergent Biosolutions Inc [EBS]
The top three institutional holders of EBS stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in EBS stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in EBS stock with ownership which is approximately 5.1238%.
